Feds Finally Release Documents Confirming Recommendation To Reschedule Cannabis Based On 'Accepted Medical Use'

Zinger Key Points
  • Cannabis is categorized as a Schedule 1 Substance, meaning it has no accepted medical value.
  • If cannabis is rescheduled, Section 280(e) of the tax code would no longer apply — and cannabis research would open further.

The U.S. government finally released hundreds of pages of documents Friday related to its ongoing review of the status of cannabis under federal law, confirming for the first time that the Department of Health and Human Services has recommended the DEA reschedule cannabis as Schedule III under the Controlled Substances Act.

The 252 pages of documents explain that cannabis “has a currently accepted medical use in treatment in the United States” and that it has a “potential for abuse less than the drugs or other substances in Schedules I and II," as first reported by Marijuana Moment. 

Federal health officials acknowledged that they conducted an analysis and found that more than 30,000 health care professionals “across 43 U.S. jurisdictions are authorized to recommend the medical use of marijuana for more than six million registered patients for at least 15 medical conditions.”

Barely a day after a government lawyer said the documents would be released in their entirety, officials made them available to Matt Zorn, the attorney who sued the government over a Freedom of Information Act request to obtain them. In October, Zorn filed a complaint in the U.S. District Court in Washington, D.C. against the HHS demanding that it produce a copy of the letter issuing the cannabis scheduling review directive.

Zorn posted an image to his On Drugs blog on Friday of a letter to DEA Director Anne Milgram in which the Office of the Assistant Secretary for Health writes that “Marijuana meets the findings for control in Schedule III set forth in 21 U.S.C. 812(b)(3).”

Stay safe folks.https://t.co/ygvqVxb1Ra

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisGovernmentNewsRegulationsPoliticsTop StoriesMarketsGeneralcannabis reschedulingDEAFreedom of Information ActHHS
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Cannabis is evolving – don’t get left behind!

Curious about what’s next for the industry and how to leverage California’s unique market?

Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!

Get your tickets now to secure your spot and avoid last-minute price hikes.